Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Moderate to Severe Nail Psoriasis
NCT01807520Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2013
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in nail psoriasis (3 arms), sponsored by Novartis. Primary endpoint: Percentage Change From Baseline in Nail Psoriasis Severity Index at 16 weeks. Started Jun 2013; status: completed.
02
Drugs
secukinumab
03
Conditions
nail psoriasis
Beyond the preview
Go deeper on NCT01807520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01807520.